MedTrace Logo

Atorvastatin Pre-Treatment Influences the Risk of Percutaneous Coronary Intervention Study

NCT00469326 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2009-01-27

No results posted yet for this study

Summary

This study investigates potential protective effect of atorvastatin pre-treatment in patient with stable coronary artery disease undergoing percutaneous coronary intervention (PCI). Patient are randomized to two groups: atorvastatin pre-treatment group (80mg atorvastatin two days before PCI) and control group (PCI without atorvastatin pretreatment). Endpoint is myocardial infarction measured by troponin I and creatine kinase myocardial band.

Conditions

Interventions

DRUG

Atorvastatin

two days 80mg atorvastatin pre-treatment before PCI

Sponsors & Collaborators

  • University Hospital, Motol

    lead OTHER

Principal Investigators

  • Josef Veselka, Prof., PhD. · Department of Cardiology, Cardiovascular Center, University Hospital Motol, Prague, Czech Republic

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-04-30
Primary Completion
2008-12-31
Completion
2008-12-31

Countries

  • Czechia

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00469326 on ClinicalTrials.gov